MGTA - マジェンタ・セラピュ―ティクス （Magenta Therapeutics Inc.）

The share price of Magenta Therapeutics Inc. (NASDAQ:MGTA) fell to $1.73 per share on Friday from $1.75. While Magenta Therapeutics Inc. has underperformed by -1.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MGTA fell by -73.83%, with highs and lows ranging from $8.49 to $0.92, […]

During the last session, Magenta Therapeutics Inc. (NASDAQ:MGTA)’s traded shares were 0.42 million, with the beta value of the company hitting 2.14. At the end of the trading day, the stock’s price was $1.80, reflecting an intraday loss of -3.74% or -$0.07. The 52-week high for the MGTA share is $8.49, that puts it down … Magenta Therapeutics Inc. (NASDAQ: MGTA) Is Up 48.89% From Its 52-Week Low; YTD, It Is Down -59.37% – What To Do Now Read More »

Goldman Sachs has downgraded Magenta Therapeutics (MGTA) from buy to neutral due to a lack of proof-of-concept generating events for one of its lead programs, MGTA-117.

https://www.investing.com/news/pro/update-goldman-sachs-downgrades-magenta-therapeutics-to-neutral-432SI-2879458

Magenta Therapeutics Inc. (NASDAQ:MGTA) shares, rose in value on Friday, 08/05/22, with the stock price up by 10.32% to the previous day’s close as strong demand from buyers drove the stock to $1.87. Actively observing the price movement in the last trading, the stock closed the session at $1.70, falling within a range of $1.65 … Magenta Therapeutics Inc. (NASDAQ: MGTA): Is It Stable And Growing? Read More »

Magenta Therapeutics Inc. (NASDAQ:MGTA) shares, rose in value on Friday, 08/05/22, with the stock price up by 10.32% to the previous day’s close as strong demand from buyers drove the stock to $1.87. Actively observing the price movement in the last trading, the stock closed the session at $1.70, falling within a range of $1.65 … Magenta Therapeutics Inc. (NASDAQ: MGTA): Is It Stable And Growing? Read More »

Magenta Therapeutics (NASDAQ: MGTA ) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Magenta Therapeutics beat estimated earnings by 12.12%, reporting an EPS of … Full story available on Benzinga.com

Magenta Therapeutics press release (MGTA): Q2 GAAP EPS of -$0.29 beats by $0.06.Cash, cash equivalents and marketable securities as of June 30, 2022, were $139.4 million

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will participate in a Gene Modulation Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference, to be held virtually, on Tuesday, August 9 th , 2022 at 9:45 a.m. ET.

Gainers Seritage Growth Properties (NYSE: SRG ) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale. Aditxt, Inc. (NASDAQ: ADTX ) shares climbed 50% to close at $0.24 on Friday after the company''s Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100. Waitr Holdings Inc. (NASDAQ: WTRH ) gained 48.5% to settle at $0.35 after the company announced a new partnership with Burq to allow deliveries from several new retail industries. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) surged 44.4% to close at $8.20. MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD ) jumped 42.1% to close at $4.25 after gaining 9% on Thursday. Kura Sushi USA, Inc. (NASDAQ: KRUS ) climbed 33.6% to close at $72.29 after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY22 sales guidance above analyst estimates.

Magenta Therapeutics Inc (MGTA) shares closed today at 1.8% above its 52 week low of $4.40, giving the company a market cap of $273M. The stock is currently up 5.2% year-to-date, down 45.9% over the past 12 months, and down 67.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 70.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.0% lower than its 5-day moving average, 6.7% lower than its 20-day moving average, and 28.4% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -248.1% The company's stock price performance over the past 12 months lags the peer average by 49.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Futures Steady After Fed-Inspired Rout As Tech, Bitcoin Slide Continues US equity futures were little changed after earlier swings as traders digested hawkish Fed minutes that sparked a global stock rout on Wednesday. As discussed yesterday, minutes from the Feds December meeting showed a growing preference for a faster path of rate hikes and a shrinking of the banks balance sheet (one which would lead to yet another market crash and even more stimulus). However, while rising rates is terrible news for tech and high duration names, it''s good news for the value sector, and investors bet while the Fed''s faster-than-expected policy tightening (which will lead to faster than expected easing) may crimp highly valued technology stocks it will offer opportunities in other equity sectors, and sure enough with Nasdaq futures bombing again, energy names like Exxon are at 2 year highs. Treasury yields extended a spike, with the 10Y rising to 1.75%, the dollar was unchanged and bitcoin''s plunge continued even though the selling in stocks has subsided.

Goldman Sachs analyst Madhu Kumar upgraded Magenta Therapeutics (MGTA) to Buy from Neutral with a price target ((PT)) of $8, up from $7. Shares up 6% premarket at $4.73

Magenta Therapeutics Inc (MGTA) shares closed today at 0.6% above its 52 week low of $4.62, giving the company a market cap of $299M. The stock is currently down 34.9% year-to-date, down 33.8% over the past 12 months, and down 64.9% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 14.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 21.9% The company's stock price performance over the past 12 months lags the peer average by 11.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of Magenta Therapeutics to its Board of Directors. Dr. Humphrey is an accomplished clinical researcher and drug developer who has shepherded numerous drugs through all phases of development from pre-IND to post-lau